8-K: Spruce Biosciences Secures Backup Bid for Eiger BioPharmaceuticals' Avexitide Assets After Auction

Spruce Biosciences has secured a backup bid to acquire Eiger BioPharmaceuticals' Avexitide assets for $34.7 million, following an auction where they were outbid.

Summary

• Spruce Biosciences entered into an asset purchase agreement on June 13, 2024, to acquire substantially all rights to Eiger BioPharmaceuticals' Avexitide assets for $10 million, subject to bankruptcy court approval.
• This agreement positioned Spruce as the 'stalking horse' bidder.
• An auction was held on June 17, 2024, where Spruce was outbid, but secured the position of back-up bidder with a net bid of $34.7 million, plus the assumption of specified contractual cure amounts up to $0.3 million.
• The sale of the assets is subject to approval by the Bankruptcy Court at a hearing scheduled for June 26, 2024.
• If the winning bidder fails to complete the acquisition, Spruce will be obligated to purchase the assets at the back-up bid price.
• If the winning bidder completes the acquisition, Spruce will receive a $0.3 million termination fee.

Sentiment

Score: 5

Explanation: The document presents a mixed situation. While Spruce has a potential acquisition opportunity, they were outbid and may not acquire the assets. The higher back-up bid price is a negative, but the termination fee provides some compensation.

Positives

• Spruce Biosciences has secured a potential acquisition of valuable assets related to Avexitide.
• The company has a fallback position to acquire the assets if the winning bidder fails to complete the purchase.
• Spruce is set to receive a $0.3 million termination fee if they do not acquire the assets.

Negatives

• Spruce was outbid in the auction, indicating a higher valuation of the assets than their initial bid.
• The final purchase price of $34.7 million is significantly higher than the initial $10 million stalking horse bid.
• The acquisition is not guaranteed and is subject to court approval and the winning bidder's actions.

Risks

• The acquisition is subject to approval by the Bankruptcy Court.
• The winning bidder may complete the acquisition, leaving Spruce with only a termination fee.
• There are risks and uncertainties associated with the company's business in general, geopolitical and macroeconomic events, and other risks described in the company's filings with the SEC.

Future Outlook

The company's future depends on the Bankruptcy Court's approval of the sale and whether the winning bidder completes the acquisition. Spruce may acquire the assets or receive a termination fee.

Industry Context

This announcement reflects the ongoing financial challenges faced by some biotechnology companies, leading to asset sales through bankruptcy proceedings. It also highlights the competitive nature of acquiring promising assets in the biotech sector.

Comparison to Industry Standards

• The use of a stalking horse bid is a common practice in bankruptcy proceedings to set a floor price for assets.
• The auction process is standard for maximizing value for creditors in bankruptcy cases.
• The back-up bidder position provides a safety net for the seller in case the winning bidder fails to close the deal.
• The $34.7 million back-up bid is a significant increase from the initial $10 million bid, suggesting a competitive market for the assets.
• Comparable transactions in the biotech sector often involve complex negotiations and court approvals.

Legal Proceedings

• The acquisition is subject to the approval of the United States Bankruptcy Court for the Northern District of Texas.

Stakeholder Impact

• Shareholders of Spruce Biosciences may see potential value from the acquisition of Avexitide assets, but also face the risk of a higher purchase price.
• Employees of Spruce Biosciences may be impacted by the potential integration of new assets and operations.
• Eiger BioPharmaceuticals' creditors will be impacted by the outcome of the asset sale.

Next Steps

• The Bankruptcy Court will review and potentially approve the sale of the Transferred Assets on June 26, 2024.
• If the winning bidder fails to complete the acquisition, Spruce will be obligated to purchase the assets.
• If the winning bidder completes the acquisition, Spruce will receive a $0.3 million termination fee.

Key Dates

Keywords

Spruce Biosciences, Eiger BioPharmaceuticals, Avexitide, Asset Purchase Agreement, Bankruptcy Court, Auction, Stalking Horse Bid, Back-up Bidder, Acquisition, Termination Fee